{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:57:25Z","timestamp":1780563445253,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gabapentin was thought to have low abuse potential, but it is increasingly being abused by people with substance use disorder in an attempt to potentiate the euphoric effects from opioids and other CNS depressants. Additionally, infants co-exposed to gabapentin and opioids during pregnancy tend to exhibit prolonged and more severe neonatal abstinence syndrome. In this study, we describe positivity rates among commonly abused drugs and rates of co-medication with gabapentin in a large dataset of umbilical cord tissue specimens (n\u2009=\u200925,422) submitted for routine newborn drug testing at a national clinical reference laboratory (ARUP Laboratories, Salt Lake City, UT, USA). Detection of prenatal drug exposure in umbilical cord tissue specimens was accomplished using a semi-quantitative liquid chromatography\u2013tandem mass spectrometry assay designed to detect 47 specific drugs and drug metabolites including opioids, stimulants, sedative-hypnotics and hallucinogens. A positive result for at least one of the measured drugs or drug metabolites was reported in 7,054 (28%) of the umbilical cord tissues analyzed. Gabapentin had a positivity rate of\u2009~2% with 562 positive results. Of the 562 gabapentin-positive samples, 395 (70%) also had a positive result for at least one other drug or drug metabolite, with the highest co-positivity rate observed for norbuprenorphine (32%, n\u2009=\u2009182) followed by amphetamine (15%, n\u2009=\u200984), buprenorphine (13%, n\u2009=\u200974), methamphetamine (12%, n\u2009=\u200968), morphine (11%, n\u2009=\u200964), fentanyl (10%, n\u2009=\u200954) and naloxone (10%, n\u2009=\u200954). Notably, the concentration of gabapentin in gabapentin-positive umbilical cord specimens was higher in buprenorphine-containing specimens as compared to specimens containing other opioids, stimulants or benzodiazepines. Identification of neonatal co-exposure to gabapentin and opioids, particularly buprenorphine, may guide clinicians in rapid initiation of monitoring and intervention for neonatal abstinence syndrome.<\/jats:p>","DOI":"10.1093\/jat\/bkaa118","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T19:11:43Z","timestamp":1598382703000},"page":"506-512","source":"Crossref","is-referenced-by-count":10,"title":["Patterns of Neonatal Co-Exposure to Gabapentin and Commonly Abused Drugs Observed in Umbilical Cord Tissue"],"prefix":"10.1093","volume":"45","author":[{"given":"Nkemakonam C","family":"Okoye","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn A","family":"McMillin","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA"},{"name":"ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"key":"2021051408474120700_R1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006","journal-title":"Current Opinion in Pharmacology"},{"key":"2021051408474120700_R2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.semcdb.2006.09.003","article-title":"\u03b12\u03b4 and the mechanism of action of gabapentin in the treatment of pain","volume":"17","author":"Maneuf","year":"2006","journal-title":"Seminars in Cell & Developmental Biology"},{"key":"2021051408474120700_R3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/RMHP.S168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Management and Healthcare Policy"},{"key":"2021051408474120700_R4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"key":"2021051408474120700_R5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"key":"2021051408474120700_R6","article-title":"Medicine Use and Spending in the U.S. A Review of 2018 and Outlook to 2023","author":"IQVIA Institute for Human Data Science"},{"key":"2021051408474120700_R7","article-title":"Physician Perspectives and Diagnostic Insights on the Evolving Drug Crisis","author":"Health Trends\u2122 Drug Misuse in America 2019"},{"key":"2021051408474120700_R8","article-title":"FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) when used with CNS depressants or in patients with lung problems","author":"U.S. Food & Drug Administration"},{"key":"2021051408474120700_R9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jpeds.2016.11.004","article-title":"An atypical withdrawal syndrome in neonates prenatally exposed to gabapentin and opioids","volume":"181","author":"Loudin","year":"2017","journal-title":"The Journal of Pediatrics"},{"key":"2021051408474120700_R10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jpeds.2019.09.029","article-title":"Identifying co-exposure to opiates and gabapentin during pregnancy","volume":"217","author":"Loudin","year":"2020","journal-title":"The Journal of Pediatrics"},{"key":"2021051408474120700_R11","article-title":"Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: Cohort study","volume":"358","author":"Huybrechts","year":"2017","journal-title":"British Medical Journal"},{"key":"2021051408474120700_R12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/FTD.0b013e3182a0d18c","article-title":"Detection of neonatal drug exposure using umbilical cord tissue and liquid chromatography time-of-flight mass spectrometry","volume":"36","author":"Marin","year":"2014","journal-title":"Therapeutic Drug Monitoring"},{"key":"2021051408474120700_R13","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.clinbiochem.2016.04.007","article-title":"Development of a liquid chromatography\u2013tandem mass spectrometry method to address the increased utilization of umbilical cord in the assessment of in utero drug exposure","volume":"49","author":"Haglock-Adler","year":"2016","journal-title":"Clinical Biochemistry"},{"key":"2021051408474120700_R14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/FTD.0000000000000485","article-title":"Detection of drug-exposed newborns","volume":"40","author":"Wabuyele","year":"2018","journal-title":"Therapeutic Drug Monitoring"},{"key":"2021051408474120700_R15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.jp.7211416","article-title":"Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium","volume":"26","author":"Montgomery","year":"2006","journal-title":"Journal of Perinatology"},{"key":"2021051408474120700_R16","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.clinbiochem.2017.03.006","article-title":"Comparison of umbilical cord tissue and meconium for the confirmation of in utero drug exposure","volume":"50","author":"Colby","year":"2017","journal-title":"Clinical Biochemistry"},{"key":"2021051408474120700_R17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clinbiochem.2016.11.026","article-title":"Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: a retrospective study at an academic medical center","volume":"50","author":"Palmer","year":"2017","journal-title":"Clinical Biochemistry"},{"key":"2021051408474120700_R18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: Ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"2021051408474120700_R19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000355268","article-title":"Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers","volume":"20","author":"Baird","year":"2014","journal-title":"European Addiction Research"},{"key":"2021051408474120700_R20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine","volume":"171","author":"Roy R. Reeves","year":"2014","journal-title":"American Journal of Psychiatry"},{"key":"2021051408474120700_R21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1176\/appi.ajp.2014.14101272","article-title":"Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky","volume":"172","author":"Smith","year":"2015","journal-title":"American Journal of Psychiatry"},{"key":"2021051408474120700_R22","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case\u2013control study","volume":"14(10)","author":"Gomes","year":"2017","journal-title":"PLoS Medicine"},{"key":"2021051408474120700_R23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1213\/00000539-200007000-00035","article-title":"Gabapentin enhances the analgesic effect of morphine in healthy volunteers","volume":"91","author":"Eckhardt","year":"2000","journal-title":"Anesthesia and Analgesia"},{"key":"2021051408474120700_R24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/WNR.0b013e328363fde8","article-title":"Gabapentin attenuates morphine tolerance through interleukin-10","volume":"25","author":"Bao","year":"2014","journal-title":"NeuroReport"},{"key":"2021051408474120700_R25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199710000-00012","article-title":"Gabapentin abuse in a cocaine user: implications for treatment?","volume":"17","author":"Markowitz","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"2021051408474120700_R26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/00952990.2015.1125493","article-title":"Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients","volume":"42","author":"Mariani","year":"2016","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"2021051408474120700_R27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15436\/2471-061X.15.007","article-title":"Gabapentin (Neurontin): an adjunct for benzodiazepine withdrawal","volume":"1","author":"Glass","year":"2015","journal-title":"Journal of Addiction and Dependence"},{"key":"2021051408474120700_R28","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMra1611832","article-title":"Treatment of benzodiazepine dependence","volume":"376","author":"Soyka","year":"2017","journal-title":"New England Journal of Medicine"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaa118\/34193155\/bkaa118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/45\/5\/506\/37933736\/bkaa118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/45\/5\/506\/37933736\/bkaa118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T23:15:48Z","timestamp":1668035748000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/45\/5\/506\/5899168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,8,29]]},"published-print":{"date-parts":[[2021,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaa118","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,8,29]]}}}